Nuplazid generic
Nuplazid is an anti-psychotic drug owned by Acadia Pharms Inc. The active ingredient in Nuplazid is pimavanserin tartrate. Nuplazid was first authorized for market use on 29 April 2016 and is available in tablet form for oral administration.
When will Nuplazid generic be available?
The generics for Nuplazid might be released after 27 August 2038, as this is the expiry date for the last patent associated with the drug. This date is subject to change if there are successful para IV filings.
Nuplazid uses
Nuplazid is primarily used for the treatment of psychosis and symptoms related to neurodegenerative diseases. It is proven to be effective in treating hallucinations and delusions associated with Parkinson's disease psychosis.
Nuplazid patent expiration
Nuplazid is protected by 15 drug patents, with the most recent set to expire on 27 August 2038. The first patent expired on 27 July 2022. More information about these patents can be found below. The longevity of these patents might delay the release of Nuplazid generic drugs.